X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AMAR REMEDIES with Gillette India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AMAR REMEDIES vs GILLETTE INDIA - Comparison Results

GILLETTE INDIA 
   Change

Gillette India is the 52% subsidiary of US shaving major - Gillette USA. The company came back into the black in 2003 after a spate of restructuring in 2001 and 2002. Gillette hived off its battery manufacturing plant (Duracell) at Manesar and also s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AMAR REMEDIES GILLETTE INDIA AMAR REMEDIES/
GILLETTE INDIA
 
P/E (TTM) x -0.5 82.1 - View Chart
P/BV x 0.1 25.1 0.2% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 AMAR REMEDIES   GILLETTE INDIA
EQUITY SHARE DATA
    AMAR REMEDIES
Jun-12
GILLETTE INDIA
Jun-16
AMAR REMEDIES/
GILLETTE INDIA
5-Yr Chart
Click to enlarge
High Rs1645,650 2.9%   
Low Rs863,805 2.3%   
Sales per share (Unadj.) Rs261.6601.3 43.5%  
Earnings per share (Unadj.) Rs17.460.8 28.6%  
Cash flow per share (Unadj.) Rs22.370.1 31.8%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs100.7263.2 38.3%  
Shares outstanding (eoy) m26.1632.59 80.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.57.9 6.1%   
Avg P/E ratio x7.277.8 9.2%  
P/CF ratio (eoy) x5.667.4 8.3%  
Price / Book Value ratio x1.218.0 6.9%  
Dividend payout %032.9 0.0%   
Avg Mkt Cap Rs m3,270154,069 2.1%   
No. of employees `000NA0.6 0.0%   
Total wages/salary Rs m1631,090 15.0%   
Avg. sales/employee Rs ThNM30,335.3-  
Avg. wages/employee Rs ThNM1,686.7-  
Avg. net profit/employee Rs ThNM3,066.7-  
INCOME DATA
Net Sales Rs m6,84419,597 34.9%  
Other income Rs m21358 5.9%   
Total revenues Rs m6,86519,954 34.4%   
Gross profit Rs m1,1313,030 37.3%  
Depreciation Rs m128304 42.1%   
Interest Rs m39846 863.3%   
Profit before tax Rs m6263,038 20.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-500-   
Tax Rs m1211,057 11.5%   
Profit after tax Rs m4551,981 23.0%  
Gross profit margin %16.515.5 106.9%  
Effective tax rate %19.334.8 55.6%   
Net profit margin %6.610.1 65.8%  
BALANCE SHEET DATA
Current assets Rs m4,9049,732 50.4%   
Current liabilities Rs m3,5815,627 63.6%   
Net working cap to sales %19.320.9 92.3%  
Current ratio x1.41.7 79.2%  
Inventory Days Days12446 272.8%  
Debtors Days Days10020 489.9%  
Net fixed assets Rs m1,6892,740 61.7%   
Share capital Rs m262326 80.4%   
"Free" reserves Rs m2,3585,973 39.5%   
Net worth Rs m2,6358,578 30.7%   
Long term debt Rs m5070-   
Total assets Rs m6,86214,241 48.2%  
Interest coverage x2.666.9 3.8%   
Debt to equity ratio x0.20-  
Sales to assets ratio x1.01.4 72.5%   
Return on assets %12.414.2 87.3%  
Return on equity %17.323.1 74.8%  
Return on capital %31.036.0 86.2%  
Exports to sales %4.02.8 142.7%   
Imports to sales %015.6 0.0%   
Exports (fob) Rs m273548 49.9%   
Imports (cif) Rs mNA3,050 0.0%   
Fx inflow Rs m273585 46.7%   
Fx outflow Rs m23,479 0.1%   
Net fx Rs m271-2,894 -9.4%   
CASH FLOW
From Operations Rs m-3132,794 -11.2%  
From Investments Rs m-4891,550 -31.5%  
From Financial Activity Rs m769-786 -97.8%  
Net Cashflow Rs m-333,559 -0.9%  

Share Holding

Indian Promoters % 25.5 34.9 73.1%  
Foreign collaborators % 0.0 40.1 -  
Indian inst/Mut Fund % 9.2 0.9 1,022.2%  
FIIs % 0.0 7.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 65.3 16.3 400.6%  
Shareholders   13,061 18,623 70.1%  
Pledged promoter(s) holding % 99.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AMAR REMEDIES With:   JYOTHY LABS  HIND. UNILEVER  BAJAJ CORP  GODREJ INDUSTRIES  COLGATE  

Compare AMAR REMEDIES With:   UNILEVER PLC. (UK)  P&G (US)  HYPERMARCAS (Brazil)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AMAR REMEDIES SHARE PRICE


Dec 11, 2013 (Close)

TRACK AMAR REMEDIES

  • Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AMAR REMEDIES 8-QTR ANALYSIS

COMPARE AMAR REMEDIES WITH

MARKET STATS